Malaysian Journal of Social Sciences and Humanities (MJSSH) (e-ISSN : 2504-8562)
2025, Volume 10, Issue 5, e003382
DOI: https://doi.org/10.47405/mjssh.v10i5.3382

REVIEW ARTICLE

Flow Cytometry in Population Health: Social, Educational, and Policy Implications of Lymphocyte Subset Analysis

Ahlam Alyazidi[1], Abdulrahman Muthanna[2], Sabariah Md Noor[3]
Malina Osman[4], Zainina Seman[5*]

[1]Department of Pathology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 Serdang, Selangor, Malaysia
Email: alyazidiahlam@gmail.com
[2]Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 Serdang, Selangor, Malaysia
Email: mansoor@upm.edu.my
[3]Department of Pathology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 Serdang, Selangor, Malaysia
Email: md_sabariah@upm.edu.my
[4]Department of Community Health, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 Serdang, Selangor, Malaysia
Email: malinaosman@upm.edu.my
[5]Department of Pathology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 Serdang, Selangor, Malaysia
Email: zainina@upm.edu.my

CORRESPONDING AUTHOR (*):
Zainina Seman
(zainina@upm.edu.my)

KEYWORDS:
Flow Cytometry
Lymphocyte Subsets
Population Health
Public Policy
Immunological Reference Ranges

CITATION:
Ahlam Alyazidi , Abdulrahman Muthanna, Sabariah Md Noor, Malina Osman, & Zainina Seman. (2025). Flow Cytometry in Population Health: Social, Educational, and Policy Implications of Lymphocyte Subset Analysis. *Malaysian Journal of Social Sciences and Humanities (MJSSH), 10*(5), e003382. https://doi.org/10.47405/mjssh.v10i5.3382

ABSTRACT

This review synthesizes current knowledge on using flow cytometry to analyze lymphocyte subsets—T, B, and NK cells—in healthy individuals, emphasizing its essential role in establishing accurate reference values for these immune cells across different ages and sexes. It highlights how demographic factors such as age, gender, and ethnicity significantly influence lymphocyte distributions, underscoring the necessity for population-specific reference ranges to ensure precise diagnosis and effective clinical decision-making. By compiling evidence from diverse populations, the review demonstrates that standardized and validated flow cytometry protocols are crucial for reliable large-scale immune monitoring, which in turn supports public health strategies and evidence-based policy development. The article also addresses the importance of interdisciplinary education and equitable access to advanced diagnostic technologies, advocating for broader training and resource distribution to maximize the clinical and research benefits of flow cytometry. Integrating methodological, clinical, and policy perspectives, the review provides a framework for harmonizing lymphocyte subset analysis, ultimately reinforcing the foundation for improved health monitoring and public health interventions worldwide.

Contribution/Originality: This study documents the current knowledge on the use of flow cytometry for lymphocyte subset analysis in healthy individuals, emphasizing its

© 2025 by the authors. Published by Secholian Publication. This article is licensed under a Creative Commons Attribution 4.0 International License (CC BY).

broader implications for population health, education, and policy. By documenting the establishment and interpretation of reference values for key lymphocyte subsets across different ages and sexes.

1. Introduction

Flow cytometry is a sophisticated laboratory technique that enables rapid, multiparametric analysis of single cells suspended in a fluid as they pass through a laser beam. By measuring both light scatter and fluorescence signals, flow cytometry can determine various physical and chemical characteristics of each cell, such as size, granularity, and the expression of specific surface or intracellular markers. This technology has become indispensable in fields like immunology and hematology, allowing for the detailed study of complex cell populations within a heterogeneous sample (Robinson et al., 2023).

A central application of flow cytometry is immunophenotyping, which involves the identification and characterization of cells based on the presence or absence of specific antigens, typically using fluorescently labeled antibodies. In the context of hematologic diseases, flow cytometric immunophenotyping is crucial for diagnosing, classifying, staging, and monitoring conditions such as leukemias and lymphomas. It enables clinicians to distinguish between normal and abnormal cell populations, identify lineage (e.g., B cells, T cells, NK cells), and detect subtle phenotypic aberrancies that may indicate disease, even when abnormal cells are present in small numbers (Gao, G. et al., 2023).

Lymphocyte subset analysis by flow cytometry is a powerful tool for evaluating the status of cellular immunity and monitoring immune-mediated diseases. By quantifying the proportions and absolute counts of different lymphocyte subsets—such as CD3+ T cells, CD4+ helper T cells, CD8+ cytotoxic T cells, CD19+ B cells, and CD56+/CD16+ NK cells—clinicians can assess immune competence, diagnose immunodeficiencies, and track disease progression or response to therapy. Reference ranges for these subsets can vary by population demographics, highlighting the importance of establishing local standards for accurate interpretation (Nguyen & Platt, 2024).

The increasing use of extended panels in research and analytical testing reflects the growing need to capture complex, dynamic changes over time and across diverse sample types, enabling deeper insights into causal relationships and trends. However, as panels become more comprehensive and data collection methods evolve, ensuring the reliability of the resulting data becomes more challenging. This is where method validation plays a critical role: it systematically confirms that analytical methods are fit for their intended purpose, yielding results that are accurate, precise, and reproducible across different conditions and laboratories. Proper method validation not only underpins confidence in the data but also ensures compliance with regulatory standards, supports sound decision-making, and prevents costly errors or misinterpretations. Ultimately, the combination of extended panels and rigorous method validation is essential for producing robust, trustworthy data that can withstand scientific, regulatory, and legal scrutiny (Abdel & El-Masry, 2021).

This review aims to evaluate the role of flow cytometry-based lymphocyte subset analysis in healthy individuals and assess its broader social, educational, and policy

© 2025 by the authors. Published by Secholian Publication. This article is licensed under a Creative Commons Attribution 4.0 International License (CC BY).

implications for population health, with the aim of informing strategies for health monitoring, public awareness, and evidence-based policy development.

2. Method

To conduct this review, a comprehensive literature search was performed using three major electronic databases: Scopus, Web of Science, and Medline. The search strategy was designed to capture the most relevant and up-to-date research articles related to the topics of interest. The following keywords and their combinations were used: "Flow Cytometry," "Lymphocyte Subsets," "Population Health," "Public Policy," and "Immunological Reference Ranges." Boolean operators (AND, OR) were employed to refine the search and ensure that all pertinent studies were included. The search was limited to articles published in English, and no restrictions were placed on the publication year to provide a broad overview of the available literature.

After identifying potentially relevant articles, titles and abstracts were screened for eligibility based on predefined inclusion and exclusion criteria. Full-text articles were then reviewed to extract data on study design, population characteristics, methodologies, main findings, and implications for population health and public policy. Data extraction was performed systematically and results were synthesized to highlight trends, gaps, and consensus in the literature. The quality of the included studies was also assessed to ensure the reliability of the review's conclusions. This rigorous approach allowed for a thorough and unbiased summary of current knowledge regarding lymphocyte subsets and their significance in population health and policy-making.

3. Flow Cytometry and Public Health

Validated flow cytometry methods are crucial in large-scale epidemiological studies and population health monitoring because they enable the high-throughput, quantitative analysis of immune cell populations across thousands of individuals with consistency and accuracy. By using standardized panels of fluorescently labeled antibodies, researchers can simultaneously assess dozens of immune cell subsets and activation markers from small blood samples, allowing for the detection of subtle changes in immune profiles at the population level (Moi et al., 2023). This capability is particularly valuable in studies examining the prevalence and dynamics of infectious diseases, such as HIV or COVID-19, where immune status and response patterns must be monitored across diverse cohorts to inform public health interventions (Moi et al., 2023; Grifoni et al., 2023). The scalability and reproducibility of validated flow cytometry protocols ensure that data generated are comparable across sites and time points, which is essential for longitudinal surveillance and for drawing robust epidemiological conclusions (Schmidt et al., 2022).

In the context of community immune surveillance, flow cytometry—especially advanced techniques like imaging flow cytometry—enables detailed monitoring of immune function, including phenotyping of immune cell subsets, assessment of cell proliferation, and measurement of cytokine production (Robinson et al., 2023). These methods provide insights into the overall immune competence of populations, help identify groups at risk for immunodeficiency or hyperactivation (as seen in autoimmune or inflammatory diseases), and support the evaluation of vaccine responses or the impact of emerging pathogens (Lionakis et al., 2023). Moreover, validated flow cytometry assays facilitate the identification of biomarkers for disease susceptibility and

© 2025 by the authors. Published by Secholian Publication. This article is licensed under a Creative Commons Attribution 4.0 International License (CC BY).

progression, supporting targeted public health strategies and the development of personalized interventions. As such, the integration of validated flow cytometry into epidemiological workflows enhances the precision and depth of immune monitoring at the community and population levels, ultimately strengthening public health surveillance and response capabilities (Moi et al., 2023; Robinson et al., 2023; Lionakis et al., 2023).

Accurate data on lymphocyte subsets are crucial for understanding population-level immune health and disease susceptibility because these subsets—such as T cells, B cells, and NK cells—play distinct roles in immune defense, and their proportions and absolute numbers can shift significantly in various diseases (Quiros-Roldan et al., 2024). For example, changes in the distribution of specific lymphocyte subsets have been shown to correlate with disease progression and prognosis in cancer and infectious diseases like HIV and COVID-19 (Dai et al., 2022; Roberts et al., 2024; Long et al., 2025). Establishing reliable reference ranges for these subsets in healthy populations enables clinicians and researchers to detect deviations that may signal immunodeficiency, heightened disease risk, or response to therapy (Timbrell, 2024). Such data underpin effective public health strategies, guide individualized patient monitoring, and facilitate early intervention, ultimately improving outcomes and advancing our understanding of immune system dynamics at the population level (Dai et al., 2022; Roberts et al., 2024).

4. Social and Policy Implications

Flow cytometry provides detailed, real-time insights into immune cell populations and their functional states, making it a powerful tool for informing public health policies. In the context of vaccination strategies, flow cytometry enables the monitoring of immune responses at the cellular level, such as the activation and memory status of T and B cells following immunization (Schmidt et al., 2022). By identifying which cellular responses correlate with protection, public health officials can optimize vaccine schedules, determine the need for booster doses, and tailor vaccination campaigns to specific populations. For example, flow cytometry has been used to assess the efficacy of vaccines by tracking the expansion of antigen-specific T cells after vaccination, providing evidence for the duration and strength of immunity (Lionakis et al., 2023).

During disease outbreaks, flow cytometry can rapidly characterize immune responses in affected populations, helping to identify individuals with recent exposure or robust immunity (Gil-Manso et al., 2022; Lionakis et al., 2023). This information supports targeted interventions, such as prioritizing vaccination or treatment for high-risk groups. Additionally, flow cytometry data can reveal shifts in immune cell populations that signal disease progression or recovery, guiding resource allocation for healthcare facilities and informing the deployment of medical personnel and supplies (Robinson et al., 2023). By integrating flow cytometry findings with epidemiological data, public health authorities can make evidence-based decisions to contain outbreaks, optimize immunization strategies, and allocate resources where they are most needed (Bollaerts et al., 2024).

Ethical considerations in the deployment of advanced diagnostic technologies, particularly those powered by artificial intelligence and genomics, are multifaceted and require a robust commitment to transparency, accountability, and ethical oversight. Healthcare organizations must be transparent with patients about how their data are used, ensuring informed consent, clear communication of potential risks, and the

© 2025 by the authors. Published by Secholian Publication. This article is licensed under a Creative Commons Attribution 4.0 International License (CC BY).

implementation of strong privacy safeguards (de Aguiar et al., 2023; Mennella et al., 2024). The sensitive nature of diagnostic and genetic data demands rigorous security protocols, including secure storage, retention policies, and advanced privacy-enhancing technologies such as federated learning and differential privacy, to prevent unauthorized access or misuse (Schmidt et al., 2022; de Aguiar et al., 2023). Moreover, ongoing ethical review and oversight are essential to assess risks, uphold patient autonomy, and maintain public trust in these rapidly evolving technologies (Mennella et al., 2024; Timbrell, 2024).

Equitable access to advanced diagnostic technologies remains a significant challenge, particularly for individuals from diverse and historically underserved populations. Disparities in access are often exacerbated by socioeconomic factors, underrepresentation in research datasets, and uneven insurance coverage, which can result in less accurate or inconclusive results for non-European ancestry groups and marginalized communities (Yang et al., 2023). To ensure that the benefits of these technologies are distributed fairly, it is crucial to design inclusive research protocols, expand insurance coverage, and develop infrastructure that supports broad access to diagnostic innovations (Moi et al., 2023; Yang et al., 2023). Addressing these challenges requires collaboration among researchers, clinicians, policymakers, and community advocates to create policies and practices that promote health equity, improve representativeness in research, and ultimately narrow rather than widen existing health disparities (Moi et al., 2023; Yang et al., 2023).

5. Educational Impact

Interdisciplinary education and training are essential for healthcare professionals, laboratory scientists, and policymakers to effectively interpret and utilize flow cytometry data. The complexity of modern flow cytometry—capable of high-dimensional, multi-parameter analysis—requires not only technical proficiency but also a deep understanding of experimental design, data acquisition, and advanced data analysis techniques, such as dimensionality reduction and clustering (Bao et al., 2023; Spies et al., 2025). Training programs now emphasize both theoretical foundations and practical skills, ensuring participants can plan experiments, select appropriate controls, and understand compensation and spillover, all of which are crucial for accurate data interpretation (Tveit et al., 2023). This holistic approach bridges the gap between laboratory science and clinical application, enabling professionals to translate complex cytometric findings into actionable insights for patient care and research (Tveit et al., 2023; Spies et al., 2025).

Moreover, as flow cytometry becomes increasingly integrated with other omics technologies and informatics, interdisciplinary collaboration is vital for maximizing its impact in biomedical research, diagnostics, and policy development (Dimitriadis et al., 2024). Healthcare professionals must be able to communicate effectively with laboratory scientists to interpret results in a clinical context, while policymakers need foundational knowledge to make informed decisions regarding technology adoption and regulatory standards (Bao et al. 2023; Tveit et al., 2023). Structured courses and workshops—often designed for diverse audiences with varying backgrounds—foster this cross-disciplinary expertise, ensuring all stakeholders can contribute to and benefit from advances in flow cytometry (Bao et al., 2023; Tveit et al., 2023; Spies et al., 2025). Ultimately, interdisciplinary education empowers teams to harness the full potential of

© 2025 by the authors. Published by Secholian Publication. This article is licensed under a Creative Commons Attribution 4.0 International License (CC BY).

flow cytometry, driving innovation and improving outcomes across healthcare and research settings (Spies et al., 2025).

To enhance medical and public health education, curricula should integrate advanced laboratory methods such as high-dimensional and spectral flow cytometry, emphasizing not only the technical skills but also the critical role these technologies play in modern diagnostics and research. Training should include hands-on modules using state-of-the-art flow cytometers capable of analyzing dozens of cellular markers simultaneously, as well as instruction in experimental design, reagent selection, sample preparation, and data interpretation (Liu et al., 2022). Incorporating simulation-based learning in clinical skills laboratories can provide students with a safe, standardized environment to practice and master these complex techniques before applying them in real-world settings (Bao et al., 2023).

Equally important is the inclusion of coursework and seminars that address the broader societal impact of flow cytometry. This should cover its transformative role in personalized medicine, infectious disease monitoring, and translational research, as well as its implications for public health policy and equitable access to advanced diagnostics (Schmidt et al., 2022; de Aguiar et al., 2023; Yang et al., 2023). Students should explore case studies—such as the use of flow cytometry in HIV/AIDS management and cancer diagnostics—to understand how technological advancements can drive better patient outcomes and influence global health strategies (Schmidt et al., 2022; Shang et al., 2023; Yang et al., 2023). By embedding both advanced technical training and societal context into the curriculum, future healthcare professionals will be better equipped to leverage laboratory innovations for improved patient care and public health (Yang et al., 2023).

6. Challenges and Opportunities

Standardizing and validating flow cytometry methods across different laboratories and regions is fraught with challenges due to the inherent complexity and variability of the technique. Major obstacles include differences in instrument hardware, lack of standardized reagents, inconsistencies in sample preparation, and divergent data analysis strategies. Variations in instrument setup—such as laser power, detector sensitivity, and software compatibility—can lead to significant discrepancies in fluorescence intensity and data output, making it difficult to compare results even when analyzing identical samples (Schmidt et al., 2022; Gao, J. et al., 2023; Long et al., 2025). Furthermore, the absence of universally accepted protocols for antibody conjugation, gating strategies, and reporting standards exacerbates variability, as does the subjective nature of data analysis in flow cytometry (Oldaker et al., 2024; Long et al., 2025).

These challenges are amplified in low-resource settings, where access to advanced instrumentation, high-quality reagents, and technical expertise may be limited. Laboratories in such regions often face additional barriers, including difficulties in sourcing standardized materials, maintaining equipment calibration, and implementing rigorous quality control measures (Schmidt et al., 2022; Gao, J. et al., 2023). Software compatibility issues and the lack of automated standardization tools further hinder the transferability and reproducibility of results between centers. While initiatives like the use of calibration beads, development of open-access protocols, and international guidelines (e.g., MIFlowCyt) offer promising steps toward harmonization, the practical implementation of these measures remains difficult in settings with constrained resources (Schmidt et al., 2022; Long et al., 2025). As a result, achieving robust

© 2025 by the authors. Published by Secholian Publication. This article is licensed under a Creative Commons Attribution 4.0 International License (CC BY).

interlaboratory standardization and validation in flow cytometry requires not only technical solutions but also sustained investment in infrastructure, training, and collaborative networks, particularly in low-resource environments.

International collaboration in flow cytometry offers significant opportunities to harmonize methodologies, share expertise, and accelerate technological advancements. Collaborative interlaboratory studies, such as those conducted under ISO standards for bacterial quantification, demonstrate how pooling resources and standardizing protocols can improve reproducibility and reliability across diverse settings (Quiros-Roldan et al., 2024). Organizations like the International Society for Advancement of Cytometry (ISAC) facilitate global networking and knowledge exchange, fostering best practices and innovation in both research and clinical diagnostics (Oldaker et al., 2024; Timbrell, 2024). Such partnerships enable the development of universally accepted reference materials and protocols, which are critical for ensuring consistent data quality and comparability worldwide, especially as flow cytometry technologies evolve rapidly with advances like spectral and mass cytometry (Long et al., 2025).

Capacity building is equally vital for expanding the effective use of flow cytometry, particularly in emerging fields like cell and gene therapies, immuno-oncology, and extracellular vesicle analysis. Training programs and shared resource laboratories help build technical expertise and infrastructure, enabling broader access to advanced cytometric techniques (Gil-Manso et al., 2022). External quality assessment (EQA) schemes play a crucial role in this context by providing standardized controls and benchmarking tools that laboratories can use to validate their assays and instrumentation performance. Initiatives such as the NIST Flow Cytometry Standards Consortium exemplify efforts to develop biological reference materials, measurement procedures, and interlaboratory studies that enhance measurement assurance and foster regulatory compliance (Moi et al., 2023). These EQA frameworks not only improve data reliability but also support the integration of artificial intelligence and machine learning applications, which depend on high-quality, standardized datasets for robust analysis (Moi et al., 2023; Lionakis et al., 2023).

7. Conclusion

Integrating biomedical advances such as flow cytometry into broader social science and policy frameworks significantly enhances public health outcomes by enabling precise, rapid, and high-throughput analysis of cellular and molecular markers critical for disease diagnosis, monitoring, and intervention. Flow cytometry's ability to identify and quantify diverse cell populations, detect disease recurrence before morphological changes, and inform individualized treatment strategies provides robust, actionable data that can be leveraged by policymakers and public health professionals to design targeted interventions, allocate resources efficiently, and monitor population health trends in real time. When combined with insights from social science—such as behavioral, demographic, and community-level factors—these biomedical data empower more holistic, equitable, and evidence-based health policies that address both biological and social determinants of health, ultimately improving disease prevention, management, and overall population well-being.

© 2025 by the authors. Published by Secholian Publication. This article is licensed under a Creative Commons Attribution 4.0 International License (CC BY).

Ethics Approval and Consent to Participate

The researchers used the research ethics provided by the Research Ethics Committee of Universiti Putra Malaysia (JKEUPM). All procedures performed in this study were conducted in accordance with the ethical standards of the institutional research committee.

Acknowledgement

The authors would like to acknowledge the Universiti Putra Malaysia (UPM) Library for providing access to the necessary articles and databases, which was essential for completing this review.

Funding

This study received no funding.

Conflict of Interest

The authors declare no conflict of Interest.

References

Abdel, G. M. T., & El-Masry, M. I. (2021). Verification of quantitative analytical methods in medical laboratories. *Journal of medical biochemistry, 40*(3), 225–236. https://doi.org/10.5937/jomb0-24764

Bao, H., Min, L., Bu, F., Wang, S., & Meng, J. (2023). Recent advances of liquid biopsy: Interdisciplinary strategies toward clinical decision-making. *Interdisciplinary Medicine, 1*(4), e20230021. https://doi.org/10.1002/INMD.20230021

Bollaerts, K., Wyndham-Thomas, C., Miller, E., Izurieta, H. S., Black, S., Andrews, N., Rubbrecht, M., Van Heuverswyn, F., & Neels, P. (2024). The role of real-world evidence for regulatory and public health decision-making for Accelerated Vaccine Deployment- a meeting report. *Biologicals : journal of the International Association of Biological Standardization, 85*, 101750. https://doi.org/10.1016/j.biologicals.2024.101750

Dai, W., Zhong, A., Qiao, Q., Wu, J., Li, W., Wu, Q., Zhou, H., Qin, S., Jiang, W., Zhang, J., & Xia, X. (2022). Characteristics of lymphocyte subset alterations in COVID-19 patients with different levels of disease severity. *Virology journal, 19*(1), 192. https://doi.org/10.1186/s12985-022-01926-8

de Aguiar, E. J., Traina, C., Jr, & Traina, A. J. M. (2023). Security and Privacy in Machine Learning for Health Systems: Strategies and Challenges. *Yearbook of medical informatics, 32*(1), 269–281. https://doi.org/10.1055/s-0043-1768731

Dimitriadis, S., Dova, L., Kotsianidis, I., Hatzimichael, E., Kapsali, E., & Markopoulos, G. S. (2024). Imaging Flow Cytometry: Development, Present Applications, and Future Challenges. *Methods and protocols, 7*(2), 28. https://doi.org/10.3390/mps7020028

Gao, G., Qi, J., Fu, L., Zhao, R., Zhang, Z., & Chen, L. (2023). Portable instrument based on color sensor chip for on-site rapid detection of dissolved sulfides in environmental water samples. *Journal of Hazardous Materials, 460*, 132440. https://doi.org/10.1016/j.jhazmat.2023.132440

© 2025 by the authors. Published by Secholian Publication. This article is licensed under a Creative Commons Attribution 4.0 International License (CC BY).

Gao, J., Luo, Y., Li, H., Zhao, Y., Zhao, J., Han, X., ... & Qian, F. (2023). Deep immunophenotyping of human whole blood by standardized multi-parametric flow cytometry analyses. *Phenomics*, *3*(3), 309-328. https://doi.org/10.1002/cyto.b.22085

Gil-Manso, S., Miguens Blanco, I., López-Esteban, R., Carbonell, D., López-Fernández, L. A., West, L., Correa-Rocha, R., & Pion, M. (2022). Comprehensive Flow Cytometry Profiling of the Immune System in COVID-19 Convalescent Individuals. *Frontiers in immunology, 12*, 793142. https://doi.org/10.3389/fimmu.2021.793142

Grifoni, A., Alonzi, T., Alter, G., Noonan, D. M., Landay, A. L., Albini, A., & Goletti, D. (2023). Impact of aging on immunity in the context of COVID-19, HIV, and tuberculosis. *Frontiers in immunology, 14*, 1146704. https://doi.org/10.3389/fimmu.2023.1146704

Lionakis, M. S., Drummond, R. A., & Hohl, T. M. (2023). Immune responses to human fungal pathogens and therapeutic prospects. Nature reviews. *Immunology, 23*(7), 433–452. https://doi.org/10.1038/s41577-022-00826-w

Liu, Y., Zhao, H., Fu, B., Jiang, S., Wang, J., & Wan, Y. (2022). Mapping Cell Phenomics with Multiparametric Flow Cytometry Assays. *Phenomics (Cham, Switzerland), 2*(4), 272–281. https://doi.org/10.1007/s43657-021-00031-0

Long, H., Tai, Y., Fan, J., Ou, X., Yan, L., Fan, Y., Feng, W., Chen, J., & Li, Y. (2025). Characteristics of peripheral lymphocyte subsets and antibodies in COVID-19-infected kidney transplantation recipients. *International immunopharmacology, 145*, 113755. https://doi.org/10.1016/j.intimp.2024.113755

Mennella, C., Maniscalco, U., De Pietro, G., & Esposito, M. (2024). Ethical and regulatory challenges of AI technologies in healthcare: A narrative review. *Heliyon, 10*(4), e26297. https://doi.org/10.1016/j.heliyon.2024.e26297

Moi, D., Zeng, B., Minnie, S. A., Bhatt, R., Wood, J., Sester, D. P., Mazzieri, R., & Dolcetti, R. (2023). Multiparametric flow cytometry to characterize vaccine-induced polyfunctional T cell responses and T cell/NK cell exhaustion and memory phenotypes in mouse immuno-oncology models. *Frontiers in immunology*, *14*, 1127896. https://doi.org/10.3389/fimmu.2023.1127896

Nguyen, A. A., & Platt, C. D. (2024). Flow Cytometry-based Immune Phenotyping of T and B Lymphocytes in the Evaluation of Immunodeficiency and Immune Dysregulation. *Clinics in Laboratory Medicine*, *44*(3), 479-493. http://dx.doi.org/10.1016/j.cll.2024.04.009

Oldaker, T., & Bakke, A. (2024). Quality Assurance and Validation in Clinical Flow Cytometry. *Manual of Molecular and Clinical Laboratory Immunology, 1*, 231-248. https://doi.org/10.1002/9781683674023.ch19

Quiros-Roldan, E., Sottini, A., Natali, P. G., & Imberti, L. (2024). The Impact of Immune System Aging on Infectious Diseases. *Microorganisms, 12*(4), 775. https://doi.org/10.3390/microorganisms12040775

Roberts, M. C., Holt, K. E., Del Fiol, G., Baccarelli, A. A., & Allen, C. G. (2024). Precision public health in the era of genomics and big data. *Nature Medicine, 30*(7), 1865–1873. https://doi.org/10.1038/s41591-024-03098-0

Robinson, J. P., Ostafe, R., Iyengar, S. N., Rajwa, B., & Fischer, R. (2023). Flow cytometry: the next revolution. *Cells*, *12*(14), 1875. https://doi.org/10.3390/cells12141875

Schmidt, B. M., Holmes, C. M., Najarian, K., Gallagher, K., Haus, J. M., Shadiow, J., Ye, W., Ang, L., Burant, A., Baker, N., Katona, A., Martin, C. L., & Pop-Busui, R. (2022). On diabetic foot ulcer knowledge gaps, innovation, evaluation, prediction markers, and clinical needs. *Journal of Diabetes and its Complications, 36*(11), 108317. https://doi.org/10.1016/j.jdiacomp.2022.108317

© 2025 by the authors. Published by Secholian Publication. This article is licensed under a Creative Commons Attribution 4.0 International License (CC BY).

Shang, M., Guo, J., & Guo, J. (2023). Point-of-care testing of infectious diseases: recent advances. *Sensors & Diagnostics, 2*(5), 1123-1144. https://doi.org/10.1039/D3SD00092C

Spies, N. C., Rangel, A., English, P., Morrison, M., O'Fallon, B., & Ng, D. P. (2025). Machine Learning Methods in Clinical Flow Cytometry. *Cancers, 17*(3), 483. https://doi.org/10.3390/cancers17030483

Timbrell, N. E. (2024). The Role and Limitations of the Reference Interval Within Clinical Chemistry and Its Reliability for Disease Detection. *British journal of biomedical science*, *81*, 12339. https://doi.org/10.3389/bjbs.2024.12339

Tveit, J., Aurlien, H., Plis, S., Calhoun, V. D., Tatum, W. O., Schomer, D. L., Arntsen, V., Cox, F., Fahoum, F., Gallentine, W. B., Gardella, E., Hahn, C. D., Husain, A. M., Kessler, S., Kural, M. A., Nascimento, F. A., Tankisi, H., Ulvin, L. B., Wennberg, R., & Beniczky, S. (2023). Automated Interpretation of Clinical Electroencephalograms Using Artificial Intelligence. *JAMA neurology, 80*(8), 805–812. https://doi.org/10.1001/jamaneurol.2023.1645

Yang, G., Mishra, M., & Perera, M. A. (2023). Multi-Omics Studies in Historically Excluded Populations: The Road to Equity. *Clinical pharmacology and therapeutics, 113*(3), 541–556. https://doi.org/10.1002/cpt.2818

© 2025 by the authors. Published by Secholian Publication. This article is licensed under a Creative Commons Attribution 4.0 International License (CC BY).